Archives: Agenda

Adaptive Oncology Trials: Improving Access and the Patient Perspective

This session explores how adaptive trial designs are changing oncology research, enabling greater flexibility in trial arms and broader use of therapies across indications. We will discuss what this means for patient access and why embedding patient perspectives early is critical to successful study design and delivery.

ROUNDTABLE SESSIONS

During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table lead/host and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

ROUNDTABLE 1: Sponsor–CRO Relationships

Building Strong Sponsor – CRO Partnerships for Efficient Trial Delivery

 

ROUNDTABLE 2:  Taking the Wheel: Gaining Control of Your eTMF During Active Trials

Jane Silverwood, Clinical Documental Management Specialist, Owkin

 

ROUNDTABLE 3: Patient Centricity, Engagement & Retention

Putting Patients First: Strategies to Recruit, Engage and Retain Participants

 

ROUNDTABLE 4:   Developing medicines from analysis of real-world data

Myles Dakin, Chairman & Founder, Hypo-Stream

 

ROUNDTABLE 5: Reserved for Surbhi Gupta, Advisor to National AI team, NHS England

Optimising Clinical Trial Feasibility: From Site Selection to Study Design

  • Assessing site capabilities, patient populations, and operational resources to ensure realistic trial execution.
  • Using data-driven approaches and analytics to predict enrollment timelines and potential bottlenecks.
  • Identifying and mitigating risks early to improve study efficiency and reduce delays.
  • Incorporating patient insights and stakeholder feedback to design feasible, patient-friendly protocols.

SPOTLIGHT – Innovation in Rare Disease

  • Analysis of Real World (Audit) Data in driving drug discovery
  • Use of RWD in driving drug discovery in rare diseases
  • Leveraging therapeutics for rare disease to larger, multiple global applications